IDEAYA Biosciences (IDYA) announced that, on May 29, 2025, the Compensation Committee of IDEAYA’s Board of Directors granted non-qualified stock options to purchase an aggregate of 664,600 shares of the Company’s common stock to nine newly hired employees. The stock options were granted under the IDEAYA Biosciences, Inc. 2023 Employment Inducement Incentive Award Plan as an inducement material to such individuals’ entering into employment with IDEAYA in accordance with Nasdaq Listing Rule 5635(c)(4).
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- IDEAYA Biosciences: Buy Rating on Anticipated Success of Darovasertib Trial and Stock Appreciation Potential
- IDEAYA Biosciences: Promising Advancements and Strategic Initiatives Drive Buy Rating
- IDEAYA Biosciences: Hold Rating Amid Promising Trials and Uncertainties
- IDEAYA Biosciences Reports Q1 2025 Financial Results
- Ideaya Biosciences price target lowered to $37 from $40 at Oppenheimer